Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page
- Check7 days agoChange DetectedThe study page now includes expanded MeSH terms and related metadata. This enhances indexing and cross-referencing without changing enrollment, design, or results.SummaryDifference51%

- Check14 days agoChange DetectedThe page revision tag changed from v3.6.4 to v3.6.5, signaling a newer version of the ClinicalTrials.gov entry. This reflects an update to the page metadata or minor content refinements without altering the study's data or eligibility details.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page footer now shows revision v3.6.4, replacing v3.6.3. This appears to be a minor system update and does not modify the study information.SummaryDifference0.1%

- Check42 days agoChange DetectedA Publications entry was added, including a PubMed-listed article about the study. A note indicates publications are automatically populated from PubMed.SummaryDifference0.3%

- Check50 days agoChange DetectedRevision: v3.6.3 was added to the page, replacing the previous Revision: v3.6.2. This reflects an internal update to the study record's versioning metadata.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.2, signaling a newer version of the page content. This change is a metadata-level update and does not modify the study details or eligibility criteria on the page.SummaryDifference0.1%

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.